changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
London, UK, 25 September 2014
BTG plc (LSE: BTG), the specialist healthcare company, today announces that Melanie Lee, PhD, CBE, FMedSci, DSc (Hons), has been appointed as part time Chief Scientific Officer to BTG, effective from 1 November 2014. As a consequence, Melanie has today retired from the Board of Directors of BTG, which she joined as a non-executive director on 29 November 2010.
Garry Watts, Chairman of BTG, commented: “On behalf of the entire Board, I would like to thank Melanie for the significant contributions she has made to BTG’s development during almost four years as a non-executive director. I am delighted she has agreed to expand her involvement with our business.”
Louise Makin, BTG’s chief executive officer, added: “With her scientific expertise and leadership skills, and existing relationships within BTG, Melanie is ideally placed to help shape our innovation and development activities as we seek to expand our portfolio with products that make a real difference to underserved patient populations.”
BTG has commenced a search for a new non-executive director.
For further information please contact:
Andy Burrows, VP Corporate and Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605
Ben Atwell/Simon Conway
+44 (0)20 3727 1000
BTG is a growing international specialist healthcare company that is developing and commercialising products targeting acute care, cancer and vascular diseases. The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programmes and products to develop and market to specialist physicians.
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com